EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies

Research output: Contribution to journalComment/debate

4 Citations (Scopus)

Abstract

An increasing number of innovative oncology monoclonal antibodies (mAbs) have been introduced into the global market, and biosimilar versions have now also been approved in Europe. Being complex to develop and difficult to manufacture, the biosimilar is a drug similar but not identical in physicochemical characteristics, efficacy, and safety to an original biological drug already approved in the European Union, for which marketing exclusivity rights have expired. Generally, the safety monitoring of biosimilars follows the same requirements that apply to all biologicals, even if specific pharmacovigilance measures exist and some of them are still being debated. The manufacturing process, immunogenicity, traceability, and extrapolation of indication are keywords which may impact on the achievement of additional knowledge about the safety of a biosimilar mAb. In this article, we aim to discuss elements that play a central role in the pharmacovigilance legislation of biosimilar mAbs.

Original languageEnglish
Pages (from-to)778-782
Number of pages5
JournalInternational Journal of Clinical Pharmacy
Volume40
Issue number4
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Biosimilar Pharmaceuticals
Pharmacovigilance
Monoclonal Antibodies
Safety
Oncology
European Union
Marketing
Legislation
Extrapolation
Pharmaceutical Preparations
Monitoring

Keywords

  • Adverse drug reaction
  • Biosimilars
  • Legislation
  • Monoclonal antibody
  • Oncology
  • Pharmacovigilance
  • Safety
  • Signal detection

ASJC Scopus subject areas

  • Pharmacy
  • Toxicology
  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{d5d872c1d1a84c9584c6bda17c5fe01a,
title = "EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies",
abstract = "An increasing number of innovative oncology monoclonal antibodies (mAbs) have been introduced into the global market, and biosimilar versions have now also been approved in Europe. Being complex to develop and difficult to manufacture, the biosimilar is a drug similar but not identical in physicochemical characteristics, efficacy, and safety to an original biological drug already approved in the European Union, for which marketing exclusivity rights have expired. Generally, the safety monitoring of biosimilars follows the same requirements that apply to all biologicals, even if specific pharmacovigilance measures exist and some of them are still being debated. The manufacturing process, immunogenicity, traceability, and extrapolation of indication are keywords which may impact on the achievement of additional knowledge about the safety of a biosimilar mAb. In this article, we aim to discuss elements that play a central role in the pharmacovigilance legislation of biosimilar mAbs.",
keywords = "Adverse drug reaction, Biosimilars, Legislation, Monoclonal antibody, Oncology, Pharmacovigilance, Safety, Signal detection",
author = "Sara Francescon and Giulia Fornasier and Paolo Baldo",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s11096-018-0709-6",
language = "English",
volume = "40",
pages = "778--782",
journal = "International Journal of Clinical Pharmacy",
issn = "2210-7703",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies

AU - Francescon, Sara

AU - Fornasier, Giulia

AU - Baldo, Paolo

PY - 2018/8/1

Y1 - 2018/8/1

N2 - An increasing number of innovative oncology monoclonal antibodies (mAbs) have been introduced into the global market, and biosimilar versions have now also been approved in Europe. Being complex to develop and difficult to manufacture, the biosimilar is a drug similar but not identical in physicochemical characteristics, efficacy, and safety to an original biological drug already approved in the European Union, for which marketing exclusivity rights have expired. Generally, the safety monitoring of biosimilars follows the same requirements that apply to all biologicals, even if specific pharmacovigilance measures exist and some of them are still being debated. The manufacturing process, immunogenicity, traceability, and extrapolation of indication are keywords which may impact on the achievement of additional knowledge about the safety of a biosimilar mAb. In this article, we aim to discuss elements that play a central role in the pharmacovigilance legislation of biosimilar mAbs.

AB - An increasing number of innovative oncology monoclonal antibodies (mAbs) have been introduced into the global market, and biosimilar versions have now also been approved in Europe. Being complex to develop and difficult to manufacture, the biosimilar is a drug similar but not identical in physicochemical characteristics, efficacy, and safety to an original biological drug already approved in the European Union, for which marketing exclusivity rights have expired. Generally, the safety monitoring of biosimilars follows the same requirements that apply to all biologicals, even if specific pharmacovigilance measures exist and some of them are still being debated. The manufacturing process, immunogenicity, traceability, and extrapolation of indication are keywords which may impact on the achievement of additional knowledge about the safety of a biosimilar mAb. In this article, we aim to discuss elements that play a central role in the pharmacovigilance legislation of biosimilar mAbs.

KW - Adverse drug reaction

KW - Biosimilars

KW - Legislation

KW - Monoclonal antibody

KW - Oncology

KW - Pharmacovigilance

KW - Safety

KW - Signal detection

UR - http://www.scopus.com/inward/record.url?scp=85051626648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051626648&partnerID=8YFLogxK

U2 - 10.1007/s11096-018-0709-6

DO - 10.1007/s11096-018-0709-6

M3 - Comment/debate

C2 - 30094558

AN - SCOPUS:85051626648

VL - 40

SP - 778

EP - 782

JO - International Journal of Clinical Pharmacy

JF - International Journal of Clinical Pharmacy

SN - 2210-7703

IS - 4

ER -